A Phase 4 interventional study of Cyclosporine A and Tacrolimus in Liver Transplant and Hepatitis C, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-12-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hepatitis C by Novartis — none open to participants now, none under way, none of them phase 3. Hepatitis C · Novartis.
Among the 10 studies in Hepatitis C by Novartis, this one is the only one that started in 2006, is one of 2 in phase 4, and was the 2nd registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 10 studies in Hepatitis C by Novartis is open now. The open studies under Hepatitis C, anywhere →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 361 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 76 across the 8 interventional studies, 22 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hepatitis C by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver. The aim of this study was to see if the frequency of liver fibrosis was different with cyclosporine microemulsion than tacrolimus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges. Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between: * Steroids administered and tapered as per local practice * interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice. The regimen selected by the center was to be given to all patients enrolled in the trial from this center.
Drug: Cyclosporine A
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges. Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between: * Steroids administered and tapered as per local practice * interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice. The regimen selected by center was to be given to all patients enrolled in trial from this center.
Drug: Tacrolimus
Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
Also known as: Neoral
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. Logistic regression on the presence of IK\>=2 was applied based on central biopsy readings only.
Time frame: 1 year post-transplant
Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2
The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died. Assessment of hepatic fibrosis was performed with liver biopsies read centrally. Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis. Higher score indicates greater fibrosis.
Time frame: 1 year post-transplant
Number of Participants With Fibrosing Cholestatic Hepatitis
Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well. The presence of FCH was reported based on the diagnosis given by the investigator.
Time frame: 1 year post-transplantation
Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
Time frame: 1 year post-transplant
Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection
Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy. BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.
Time frame: 1 year post-transplant
Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)
BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
Time frame: 1 year post-transplant
Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis
Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.
Time frame: 1 year post-transplant
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis.
Time frame: 1 year post-transplant
Mean Value of Liver Function Tests at 1 Year Post-transplantation
The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant: * Serum glutamic pyruvic transaminase (SGPT) * Serum Glutamic Oxaloacetic Transaminase (SGOT) * Bilirubin * Alkaline Phosphate * γ-Glutamyltransferase (GGT)
Time frame: 1 year post-transplant
Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant
HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.
Time frame: Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
Percentage of Participants With an Increase of at Least 1 Stage in Fibrosis
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.
Time frame: Between 1 and 2 years
Mean Fibrosis Score
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).
Time frame: At 1and 2 years and its evolution over time
| Milestone | Cyclosporin A | Tacrolimus |
|---|---|---|
| Started | 184 | 172 |
| Intent to treat (itt) population | 182 | 169 |
| Modified itt | 101 | 96 |
| Completed | 137 | 138 |
| Not completed | 47 | 34 |
| Withdrew: Subject withdrew consent | 11 | 7 |
| Withdrew: Lost to follow-up | 6 | 1 |
| Withdrew: Death | 12 | 10 |
| Withdrew: Missing | 18 | 16 |
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. Logistic regression on the presence of IK\>=2 was applied based on central biopsy readings only.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant | 63 | 52 |
The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died. Assessment of hepatic fibrosis was performed with liver biopsies read centrally. Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis. Higher score indicates greater fibrosis.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2 | 77 | 71 |
Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well. The presence of FCH was reported based on the diagnosis given by the investigator.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Number of Participants With Fibrosing Cholestatic Hepatitis | 9 | 6 |
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Death | 15 | 15 |
| Graft loss | 8 | 13 |
| Death or Graft loss | 19 | 23 |
| Graft loss with re-transplantation | 3 | 8 |
Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy. BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Treated acute rejection | 28 | 22 |
| Biopsy prove acute rejection (BPAR) | 28 | 19 |
| Sub-clinical rejection | 4 | 4 |
BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR) | 45 | 42 |
Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis | 16 | 17 |
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis.
| Participants | Cyclosporin A | Tacrolimus |
|---|---|---|
| Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population) | 63 | 54 |
The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant: * Serum glutamic pyruvic transaminase (SGPT) * Serum Glutamic Oxaloacetic Transaminase (SGOT) * Bilirubin * Alkaline Phosphate * γ-Glutamyltransferase (GGT)
| IU/L | Cyclosporin A | Tacrolimus |
|---|---|---|
| SGPT (n= 112, 112) | 100.5 ± 178.8 | 81.7 ± 82.5 |
| SGOT (n= 112,112) | 92.0 ± 122.3 | 72.8 ± 98.2 |
| Bilirubin (n= 111, 115) | 40.3 ± 85.5 | 19.3 ± 27.9 |
| Alkaline Phosphate (n= 111, 115) | 174.7 ± 152.9 | 152.9 ± 127.3 |
| GGT (n= 103, 110) | 182.2 ± 224.3 | 168.5 ± 278.7 |
HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.
| IU/µL | Cyclosporin A | Tacrolimus |
|---|---|---|
| Day 1 (n=116, 111) | 0.71 ± 0.887 | 0.62 ± 0.809 |
| Day 3 (n= 136, 120) | 0.98 ± 1.112 | 0.91 ± 1.024 |
| Day 8 (n= 122, 117) | 1.58 ± 1.569 | 1.45 ± 1.557 |
| Day 29 (n=128, 109) | 2.56 ± 1.658 | 2.74 ± 1.439 |
| Month 6 (n=96, 98) | 3.45 ± 1.069 | 3.14 ± 1.332 |
| Month 12 (n= 85, 88) | 3.17 ± 1.246 | 3.13 ± 1.385 |
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.
No measurements were reported for this outcome.
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporin A | — | 148/184 (80.4%) | 182/184 (98.9%) |
| Tacrolimus | — | 138/172 (80.2%) | 167/172 (97.1%) |
| Event | Cyclosporin A | Tacrolimus |
|---|---|---|
| Hepatitis CInfections and infestations | 77/184 | 65/172 |
| Liver function test abnormalInvestigations | 14/184 | 9/172 |
| Renal failure acuteRenal and urinary disorders | 14/184 | 6/172 |
| PyrexiaGeneral disorders | 13/184 | 9/172 |
| Liver transplant rejectionImmune system disorders | 11/184 | 7/172 |
| Complications of transplanted liverInjury, poisoning and procedural complications | 3/184 | 10/172 |
| Abdominal painGastrointestinal disorders | 3/184 | 9/172 |
| CholangitisHepatobiliary disorders | 9/184 | 2/172 |
| Bile duct stenosisHepatobiliary disorders | 8/184 | 3/172 |
| SepsisInfections and infestations | 8/184 | 5/172 |
| Event | Cyclosporin A | Tacrolimus |
|---|---|---|
| HypertensionVascular disorders | 92/184 | 69/172 |
| InsomniaPsychiatric disorders | 65/184 | 64/172 |
| ConstipationGastrointestinal disorders | 64/184 | 62/172 |
| NauseaGastrointestinal disorders | 55/184 | 59/172 |
| Procedural painInjury, poisoning and procedural complications | 50/184 | 59/172 |
| Oedema peripheralGeneral disorders | 61/184 | 58/172 |
| DiarrhoeaGastrointestinal disorders | 41/184 | 57/172 |
| AnaemiaBlood and lymphatic system disorders | 51/184 | 54/172 |
| HyperglycaemiaMetabolism and nutrition disorders | 46/184 | 49/172 |
| PyrexiaGeneral disorders | 52/184 | 47/172 |
| Age Continuous(years) | Cyclosporin A | Tacrolimus | Total |
|---|---|---|---|
| Mean | 54.4 ± 6.9 | 54.4 ± 7.1 | 54.4 ± 7.0 |
| Age, Customized(Participants) | Cyclosporin A | Tacrolimus | Total |
|---|---|---|---|
| < 65 years | 163 | 154 | 317 |
| ≥ 65 years | 19 | 15 | 34 |
| Sex: Female, Male(Participants) | Cyclosporin A | Tacrolimus | Total |
|---|---|---|---|
| Female | 57 | 48 | 105 |
| Male | 125 | 121 | 246 |
The record gives a start of Jan 2006 and a primary completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclosporine · Tacrolimus